Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9791325 | 0.88 | EGFR (0.56) | EGFRTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8743684 | 0.79 | EGFR (0.54) | EGFRTSHRALOX15MEN1KMT2A | |
| SCHEMBL3094764 | 0.78 | EGFR (0.52) | EGFRTSHRCES2CES1MEN1 | |
| SCHEMBL14698829 | 0.77 | EGFR (0.47) | EGFRCES2CES1MEN1KMT2A | |
| SCHEMBL15613572 | 0.77 | EGFR (0.47) | EGFRALOX15CES2CES1MEN1 | |
| SCHEMBL15669600 | 0.77 | EGFR (0.47) | EGFRMEN1KMT2AALDH1A1CA1 | |
| SCHEMBL18955999 | 0.77 | MAPK1 (0.44) | EGFRTSHRALOX15CES2CES1 | |
| SCHEMBL16886108 | 0.77 | EGFR (0.47) | EGFRCES2CES1SRD5A2MEN1 | |
| SCHEMBL4657618 | 0.76 | GABRA1 (0.56) | TSHRALOX15CES2CES1GABRA1 | |
| SCHEMBL18956061 | 0.76 | POLB (0.48) | TSHRALOX15CES2CES1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| EP-3386591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | EGFR 495/4885TSHR 3886/4885ALOX15 3722/4885 |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | EGFR 992/4885TSHR 759/4885ALOX15 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.